Skip to main content
. Author manuscript; available in PMC: 2019 Oct 28.
Published in final edited form as: Arch Toxicol. 2018 Jul 19;92(9):2859–2874. doi: 10.1007/s00204-018-2268-y

Figure 2. Differential expression of RXR heterodimer partners (A) and nuclear receptor coregulators (B) in BM-MSCs undergoing osteogenic differentiation and treated with PPAR/RXR ligands.

Figure 2.

Figure 2.

Primary bone marrow cells were isolated from female, 8 week old, C57BL/6J mice, plated, and allowed to adhere for 7 days, and undifferentiated cultures were harvested at this time. In experimental cultures, the medium was replaced with basal medium supplemented with osteogenic additives, β-glycerol phosphate, ascorbate, insulin and dexamethasone. Cultures were treated with Vh (DMSO, 0.1%), Rosiglitazone (Rosi, 100 nM), LG100268 (LG268, 100 nM) or TBT (80 nM). After 4 days of culture, cells were harvested and analyzed for gene expression using microarray. The heatmaps display the significant differentially expressed (A) nuclear receptors and (B) coregulators (fdr<0.05). N = 4 independent bone marrow cultures.